.png)
由于全球疫情的影響，本次簽約采用線上線下結(jié)合的創(chuàng)新方式，不僅在線上匯集了來自中國(guó)香港、泰國(guó)以及以色列的Teva伙伴們，梯瓦大中華區(qū)總經(jīng)理Larry Merizalde與在現(xiàn)場(chǎng)參會(huì)的上海醫(yī)藥執(zhí)行董事、副總裁，上藥控股總經(jīng)理李永忠更是通過科技創(chuàng)新手段同時(shí)在戰(zhàn)略簽約板上簽名，讓分布在全球的伙伴們共同見證！
.png)
.png)
.png)
.png)
上藥控股助理總經(jīng)理、上藥國(guó)際供應(yīng)鏈總經(jīng)理宋潞潞表示，非常榮幸可以現(xiàn)場(chǎng)見證梯瓦與上藥控股的戰(zhàn)略合作，也對(duì)梯瓦的支持與信任表示衷心的感謝。上藥控股從一個(gè)區(qū)域性公司發(fā)展成為目前中國(guó)最大的醫(yī)藥商業(yè)公司之一，秉承“服務(wù)為榮”的經(jīng)營(yíng)理念，得到了眾多像梯瓦一樣全球領(lǐng)先的制藥企業(yè)的認(rèn)可。同時(shí)，在未來，全新的進(jìn)口平臺(tái)—上藥國(guó)際供應(yīng)鏈有限公司也將依靠臨港自由貿(mào)易區(qū)的優(yōu)惠政策，整合全球資源配置，爭(zhēng)取為梯瓦提供更便利、更優(yōu)質(zhì)的服務(wù)。
.png)
作為治療與亨廷頓病有關(guān)的舞蹈病和成人遲發(fā)性運(yùn)動(dòng)障礙的有效藥物，依托對(duì)罕見病有益的國(guó)家政策，安泰坦®Austedo®將會(huì)為更多的中國(guó)患者帶來福音。同時(shí)，上海醫(yī)藥作為中國(guó)最大的藥品進(jìn)口分銷平臺(tái)，相信在未來一定可以與梯瓦共同努力，推動(dòng)中國(guó)醫(yī)療事業(yè)的蓬勃發(fā)展。
.png)
背 景 介 紹 Background Information 亨廷頓?。℉D）是一種罕見的致命的神經(jīng)退化性疾病，亞洲每十萬人中大約有0.4人患病，平均發(fā)病年齡為40歲。舞蹈?。o意識(shí)的、隨機(jī)和突然的扭動(dòng)和/或轉(zhuǎn)動(dòng)）是這種疾病最為顯著的表現(xiàn)之一，發(fā)生在大約90%的病人當(dāng)中。 About chorea associated with Huntington's disease (HD) Huntington's disease is a rare but fatal neurodegenerative disease, affecting about 0.4 per 100,000 people in Asia, with an average age of 40 years. Chorea (involuntary, random and sudden twists and/or turns) is one of the most prominent signs of the disease and occurs in approximately 90% of patients. 遲發(fā)性運(yùn)動(dòng)障礙（TD）是一種使人衰弱的運(yùn)動(dòng)紊亂，以舌頭、嘴唇、臉、軀體和四肢部位的重復(fù)且不可控的運(yùn)動(dòng)為特征。TD在長(zhǎng)期接受抗精神病藥治療的中國(guó)的精神分裂癥患者當(dāng)中的患病率為33.7%，可能是由某些用于治療精神健康狀況的藥物引起的，這意味著使用這些藥物的精神分裂癥患者中有三分之一可能患有TD。 About Tardive Dyskinesia (TD) in adults Tardive Dyskinesia is a debilitating movement disorder characterized by repetitive and uncontrollable movements of the tongue, lips, face, body, and limbs. TD has a prevalence of 33.7% among Chinese schizophrenia patients receiving long-term antipsychotic treatment and may be caused by certain drugs used to treat mental health conditions, meaning that one-third of schizophrenics using these drugs may have TD. 梯瓦是一家全球性的醫(yī)藥公司，也是全球最大的仿制藥公司，成立于1901年。同時(shí)，致力于成為全球仿制藥和生物制藥的領(lǐng)導(dǎo)者，開發(fā)及生產(chǎn)優(yōu)質(zhì)仿制藥、創(chuàng)新的專科藥物及藥物活性成分，以提高和改善病患的生活質(zhì)量。 About Teva Founded in 1901, Teva is a global pharmaceutical company, as well as the largest generic drug company in the world. Meanwhile, Teva is committed to being a global leader in generic drugs and biopharmaceuticals, developing and producing quality generic drugs, innovative specialty drugs and active ingredients to improve living quality of patients.
安泰坦®是梯瓦創(chuàng)新研發(fā)的原研藥，于2017年4月獲得美國(guó)FDA批準(zhǔn)，是FDA首次批準(zhǔn)的氘代產(chǎn)品，也是針對(duì)與亨廷頓病有關(guān)的舞蹈病的歷史上第二個(gè)藥物；在美國(guó)的獲批適應(yīng)癥包括與亨廷頓病（HD）有關(guān)的舞蹈病以及成人遲發(fā)性運(yùn)動(dòng)障礙（TD）。其中TD適應(yīng)癥被批準(zhǔn)為突破性治療。FDA對(duì)安泰坦®的批準(zhǔn)代表了HD患者的一個(gè)重要的新治療選擇。 About Austedo® Austedo®, a drug innovatively developed by Teva, was approved by FDA in April 2017. It is the first FDA approved deuterium product and the second drug in the history related to chorea associated with Huntington's disease (HD). Approved indications in the United States include Chorea associated with Huntington's disease (HD) and Tardive Dyskinesia (TD) in adults. The TD indication was approved as a breakthrough therapy. FDA approval of Austedo® represents an important new treatment option for HD patients.